Skip to main content
Erschienen in: Inflammation 6/2020

26.06.2020 | Original Article

Inhibition of miR-497-3p Downregulates the Expression of Procalcitonin and Ameliorates Bacterial Pneumonia in Mice

verfasst von: Wenlong Wang, Yitang Zhu, Linlin Yin, Yaoyao Deng, Guoxian Chu, Supin Liu

Erschienen in: Inflammation | Ausgabe 6/2020

Einloggen, um Zugang zu erhalten

Abstract

Pneumonia is usually caused by a wide variety of pathogen infection. The underlying mechanism contributing to pneumonia remains elusive. Here, the role of microRNA-497-3p (miR-497-3p) was explored in bacterial pneumonia. The expression levels of miR-497-3p and procalcitonin (PCT) in patient serum were detected by real-time polymerase chain reaction (RT-PCR) and enzyme-linked immunosorbent assay (ELISA), respectively. The interaction between miR-497-3p and PCT was further verified in A549 cell line. To further explore the role of miR-497-3p in pneumonia, mouse model of bacterial pneumonia was established via Sp TIGR4 strain (SpT4) infection. Subsequently, LV-miR-497-3p sponge was administrated in mice with bacterial pneumonia. The severity of pneumonia and inflammatory response were evaluated. Serum miR-497-3p and PCT levels increased in patients with bacterial pneumonia and miR-497-3p level positively corrected with the PCT level. The functional assay demonstrated that CALCA is the target of miR-497-3p in the A549 cell line. In mice with bacterial pneumonia, both miR-497-3p and PCT levels were upregulated after SpT4 infection. LV-miR-497-3p sponge administration attenuated pneumonia, accompanied with increasing gain of bodyweight and blood oxygen levels, as well as uninjured lungs. miR-497-3p inhibition attenuates the expression of C-reactive protein (CRP) and inflammatory cytokines in lung tissues of SpT4-infected mice, including nterleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α). In conclusion, inhibition of miR-497-3p downregulates the expression of procalcitonin and ameliorates bacterial pneumonia in mice.
Literatur
1.
Zurück zum Zitat Mandell, L.A. 2015. Community-acquired pneumonia: an overview. Postgraduate Medicine 127: 607–615.CrossRef Mandell, L.A. 2015. Community-acquired pneumonia: an overview. Postgraduate Medicine 127: 607–615.CrossRef
2.
Zurück zum Zitat Thomas, C.F., Jr., and A.H. Limper. 2004. Pneumocystis pneumonia. The New England Journal of Medicine 350: 2487–2498.CrossRef Thomas, C.F., Jr., and A.H. Limper. 2004. Pneumocystis pneumonia. The New England Journal of Medicine 350: 2487–2498.CrossRef
3.
Zurück zum Zitat Pfuntner, A., L.M. Wier, and C. Stocks. 2006. Most frequent conditions in U.S. hospitals, 2010: Statistical Brief #148. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. Rockville: Agency for Healthcare Research and Quality (US). Pfuntner, A., L.M. Wier, and C. Stocks. 2006. Most frequent conditions in U.S. hospitals, 2010: Statistical Brief #148. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. Rockville: Agency for Healthcare Research and Quality (US).
4.
Zurück zum Zitat Matuschak, G.M., and A.J. Lechner. 2010. Acute lung injury and the acute respiratory distress syndrome: pathophysiology and treatment. Missouri Medicine 107: 252–258.PubMedPubMedCentral Matuschak, G.M., and A.J. Lechner. 2010. Acute lung injury and the acute respiratory distress syndrome: pathophysiology and treatment. Missouri Medicine 107: 252–258.PubMedPubMedCentral
5.
Zurück zum Zitat Jamieson, A.M., L. Pasman, S. Yu, P. Gamradt, R.J. Homer, T. Decker, and R. Medzhitov. 2013. Role of tissue protection in lethal respiratory viral-bacterial coinfection. Science 340: 1230–1234.CrossRef Jamieson, A.M., L. Pasman, S. Yu, P. Gamradt, R.J. Homer, T. Decker, and R. Medzhitov. 2013. Role of tissue protection in lethal respiratory viral-bacterial coinfection. Science 340: 1230–1234.CrossRef
6.
Zurück zum Zitat Skalski, J.H., T.J. Kottom, and A.H. Limper. 2015. Pathobiology of Pneumocystis pneumonia: life cycle, cell wall and cell signal transduction. FEMS Yeast Research 15: fov046.CrossRef Skalski, J.H., T.J. Kottom, and A.H. Limper. 2015. Pathobiology of Pneumocystis pneumonia: life cycle, cell wall and cell signal transduction. FEMS Yeast Research 15: fov046.CrossRef
7.
Zurück zum Zitat Marriott, H.M., and D.H. Dockrell. 2006. Streptococcus pneumoniae: the role of apoptosis in host defense and pathogenesis. The International Journal of Biochemistry & Cell Biology 38: 1848–1854.CrossRef Marriott, H.M., and D.H. Dockrell. 2006. Streptococcus pneumoniae: the role of apoptosis in host defense and pathogenesis. The International Journal of Biochemistry & Cell Biology 38: 1848–1854.CrossRef
8.
Zurück zum Zitat Henig, O., and K.S. Kaye. 2017. Bacterial pneumonia in older adults. Infectious Disease Clinics of North America 31: 689–713.CrossRef Henig, O., and K.S. Kaye. 2017. Bacterial pneumonia in older adults. Infectious Disease Clinics of North America 31: 689–713.CrossRef
9.
Zurück zum Zitat Aujla, S.J., Y.R. Chan, M. Zheng, M. Fei, D.J. Askew, D.A. Pociask, T.A. Reinhart, F. McAllister, J. Edeal, K. Gaus, S. Husain, J.L. Kreindler, P.J. Dubin, J.M. Pilewski, M.M. Myerburg, C.A. Mason, Y. Iwakura, and J.K. Kolls. 2008. IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia. Nature Medicine 14: 275–281.CrossRef Aujla, S.J., Y.R. Chan, M. Zheng, M. Fei, D.J. Askew, D.A. Pociask, T.A. Reinhart, F. McAllister, J. Edeal, K. Gaus, S. Husain, J.L. Kreindler, P.J. Dubin, J.M. Pilewski, M.M. Myerburg, C.A. Mason, Y. Iwakura, and J.K. Kolls. 2008. IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia. Nature Medicine 14: 275–281.CrossRef
10.
Zurück zum Zitat Bartel, D.P. 2004. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281–297.CrossRef Bartel, D.P. 2004. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281–297.CrossRef
11.
Zurück zum Zitat Croce, C.M., and G.A. Calin. 2005. miRNAs, cancer, and stem cell division. Cell 122: 6–7.CrossRef Croce, C.M., and G.A. Calin. 2005. miRNAs, cancer, and stem cell division. Cell 122: 6–7.CrossRef
12.
Zurück zum Zitat Guo, S., Y. Chen, J. Liu, J. Yang, C. Yang, T. Zhang, K. Jiang, Z. Wu, A. Shaukat, and G. Deng. 2019. miR-497a-5p attenuates lipopolysaccharide-induced inflammatory injury by targeting IRAK2. Journal of Cellular Physiology 234: 22874–22883.CrossRef Guo, S., Y. Chen, J. Liu, J. Yang, C. Yang, T. Zhang, K. Jiang, Z. Wu, A. Shaukat, and G. Deng. 2019. miR-497a-5p attenuates lipopolysaccharide-induced inflammatory injury by targeting IRAK2. Journal of Cellular Physiology 234: 22874–22883.CrossRef
13.
Zurück zum Zitat Ma, W., Y. Kang, L. Ning, J. Tan, H. Wang, and Y. Ying. 2017. Identification of microRNAs involved in gefitinib resistance of non-small-cell lung cancer through the insulin-like growth factor receptor 1 signaling pathway. Experimental and Therapeutic Medicine 14: 2853–2862.CrossRef Ma, W., Y. Kang, L. Ning, J. Tan, H. Wang, and Y. Ying. 2017. Identification of microRNAs involved in gefitinib resistance of non-small-cell lung cancer through the insulin-like growth factor receptor 1 signaling pathway. Experimental and Therapeutic Medicine 14: 2853–2862.CrossRef
14.
Zurück zum Zitat Self, W.H., R.A. Balk, C.G. Grijalva, D.J. Williams, Y. Zhu, E.J. Anderson, G.W. Waterer, D.M. Courtney, A.M. Bramley, C. Trabue, S. Fakhran, A.J. Blaschke, S. Jain, K.M. Edwards, and R.G. Wunderink. 2017. Procalcitonin as a marker of etiology in adults hospitalized with community-acquired pneumonia. Clinical Infectious Diseases 65: 183–190.CrossRef Self, W.H., R.A. Balk, C.G. Grijalva, D.J. Williams, Y. Zhu, E.J. Anderson, G.W. Waterer, D.M. Courtney, A.M. Bramley, C. Trabue, S. Fakhran, A.J. Blaschke, S. Jain, K.M. Edwards, and R.G. Wunderink. 2017. Procalcitonin as a marker of etiology in adults hospitalized with community-acquired pneumonia. Clinical Infectious Diseases 65: 183–190.CrossRef
15.
Zurück zum Zitat Wang, Y., B. Jiang, Y. Guo, W. Li, Y. Tian, G.F. Sonnenberg, J.N. Weiser, X. Ni, and H. Shen. 2017. Cross-protective mucosal immunity mediated by memory Th17 cells against Streptococcus pneumoniae lung infection. Mucosal Immunology 10: 250–259.CrossRef Wang, Y., B. Jiang, Y. Guo, W. Li, Y. Tian, G.F. Sonnenberg, J.N. Weiser, X. Ni, and H. Shen. 2017. Cross-protective mucosal immunity mediated by memory Th17 cells against Streptococcus pneumoniae lung infection. Mucosal Immunology 10: 250–259.CrossRef
16.
Zurück zum Zitat Yook, Y.S., J.S. Jeon, J.O. Park, and J.K. Kim. 2018. Laboratory investigation of trends in bacterial pneumonia in Cheonan, Korea, from January 2008 to September 2017. Journal of Microbiology and Biotechnology 28: 1730–1735.CrossRef Yook, Y.S., J.S. Jeon, J.O. Park, and J.K. Kim. 2018. Laboratory investigation of trends in bacterial pneumonia in Cheonan, Korea, from January 2008 to September 2017. Journal of Microbiology and Biotechnology 28: 1730–1735.CrossRef
17.
Zurück zum Zitat Ambros, V. 2004. The functions of animal microRNAs. Nature 431: 350–355.CrossRef Ambros, V. 2004. The functions of animal microRNAs. Nature 431: 350–355.CrossRef
18.
Zurück zum Zitat Bartel, D.P. 2009. MicroRNAs: target recognition and regulatory functions. Cell 136: 215–233.CrossRef Bartel, D.P. 2009. MicroRNAs: target recognition and regulatory functions. Cell 136: 215–233.CrossRef
19.
Zurück zum Zitat Shen, L., J. Li, L. Xu, J. Ma, H. Li, X. Xiao, et al. 2012. miR-497 induces apoptosis of breast cancer cells by targeting Bcl-w. Experimental and Therapeutic Medicine 3: 475–480.CrossRef Shen, L., J. Li, L. Xu, J. Ma, H. Li, X. Xiao, et al. 2012. miR-497 induces apoptosis of breast cancer cells by targeting Bcl-w. Experimental and Therapeutic Medicine 3: 475–480.CrossRef
20.
Zurück zum Zitat Zhu, W., D. Zhu, S. Lu, T. Wang, J. Wang, B. Jiang, Y. Shu, and P. Liu. 2012. miR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2. Medical Oncology 29: 384–391.CrossRef Zhu, W., D. Zhu, S. Lu, T. Wang, J. Wang, B. Jiang, Y. Shu, and P. Liu. 2012. miR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2. Medical Oncology 29: 384–391.CrossRef
21.
Zurück zum Zitat Chen, X., C. Shi, C. Wang, W. Liu, Y. Chu, Z. Xiang, K. Hu, P. Dong, and X. Han. 2017. The role of miR-497-5p in myofibroblast differentiation of LR-MSCs and pulmonary fibrogenesis. Scientific Reports 7: 40958.CrossRef Chen, X., C. Shi, C. Wang, W. Liu, Y. Chu, Z. Xiang, K. Hu, P. Dong, and X. Han. 2017. The role of miR-497-5p in myofibroblast differentiation of LR-MSCs and pulmonary fibrogenesis. Scientific Reports 7: 40958.CrossRef
Metadaten
Titel
Inhibition of miR-497-3p Downregulates the Expression of Procalcitonin and Ameliorates Bacterial Pneumonia in Mice
verfasst von
Wenlong Wang
Yitang Zhu
Linlin Yin
Yaoyao Deng
Guoxian Chu
Supin Liu
Publikationsdatum
26.06.2020
Verlag
Springer US
Erschienen in
Inflammation / Ausgabe 6/2020
Print ISSN: 0360-3997
Elektronische ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-020-01279-w

Weitere Artikel der Ausgabe 6/2020

Inflammation 6/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Vorhofflimmern bei Jüngeren gefährlicher als gedacht

06.05.2024 Vorhofflimmern Nachrichten

Immer mehr jüngere Menschen leiden unter Vorhofflimmern. Betroffene unter 65 Jahren haben viele Risikofaktoren und ein signifikant erhöhtes Sterberisiko verglichen mit Gleichaltrigen ohne die Erkrankung.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.